lonafarnib has been researched along with bromodeoxyuridine in 1 studies
| Studies (lonafarnib) | Trials (lonafarnib) | Recent Studies (post-2010) (lonafarnib) | Studies (bromodeoxyuridine) | Trials (bromodeoxyuridine) | Recent Studies (post-2010) (bromodeoxyuridine) |
|---|---|---|---|---|---|
| 224 | 34 | 90 | 13,164 | 71 | 1,816 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bishop, WR; Bryant, MS; Catino, JJ; Chen, J; Dell, J; Doll, RJ; Ferrari, E; Girijavallabhan, VM; Korfmacher, WA; Lee, S; Lin, CC; Lipari, P; Liu, M; Malkowski, M; Mallams, AK; Nielsen, L; Njoroge, FG; Nomeir, AA; Prioli, N; Remiszewski, S; Sinha, D; Syed, J; Taveras, AG; Wang, L; Yaremko, B | 1 |
1 other study(ies) available for lonafarnib and bromodeoxyuridine
| Article | Year |
|---|---|
Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice.
Topics: 3T3 Cells; Administration, Oral; Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Bromodeoxyuridine; Cell Division; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Genes, ras; Humans; Macaca fascicularis; Male; Mice; Neoplasm Transplantation; Neoplasms, Experimental; Piperidines; Pyridines; Rats; Transplantation, Heterologous | 1998 |